TipRanks
Xuanzhu Biopharmaceutical Co., Ltd. Class H (HK:2575)
:2575
Hong Kong Market
2575
Xuanzhu Biopharmaceutical Co., Ltd. Class H
RESEARCH TOOLSreports
Want to see HK:2575 full AI Analyst Report?

Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) Ratios

2 Followers

Xuanzhu Biopharmaceutical Co., Ltd. Class H Ratios

HK:2575's free cash flow for Q2 2026 was HK$0.22. For the 2026 fiscal year, HK:2575's free cash flow was decreased by HK$ and operating cash flow was HK$-1.14. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 3.69 3.75 2.06 3.79 8.55
Quick Ratio
 3.27 3.36 1.74 3.35 8.02
Cash Ratio
 2.50 3.10 0.92 1.00 2.39
Solvency Ratio
 -0.69 -0.78 -2.22 -1.28 -4.33
Operating Cash Flow Ratio
 -0.91 -0.90 -0.55 -0.81 -4.27
Short-Term Operating Cash Flow Coverage
 0.00 -309.41 -118.21 -22.61 -61.37
Net Current Asset Value
HK$ 575.53MHK$ 626.32MHK$ 137.38MHK$ 365.17MHK$ 769.22M
Leverage Ratios
Debt-to-Assets Ratio
 <0.01 <0.01 <0.01 0.01 0.02
Debt-to-Equity Ratio
 <0.01 <0.01 <0.01 0.02 0.02
Debt-to-Capital Ratio
 <0.01 <0.01 <0.01 0.02 0.02
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 1.20 1.20 1.25 1.19 1.09
Debt Service Coverage Ratio
 0.00 -257.93 -466.13 -42.44 -62.07
Interest Coverage Ratio
 0.00 -1.88K -1.85K -290.58 -328.92
Debt to Market Cap
 0.00 <0.01 <0.01 <0.01 <0.01
Interest Debt Per Share
 <0.01 <0.01 <0.01 0.04 0.07
Net Debt to EBITDA
 3.11 3.47 0.31 0.47 0.39
Profitability Margins
Gross Profit Margin
34.41%38.82%-38.61%-110848.08%0.00%
EBIT Margin
-189.09%-450.85%-1847.94%-1032406.20%0.00%
EBITDA Margin
-161.41%-392.80%-1735.77%-921489.15%0.00%
Operating Profit Margin
-182.18%-450.85%-1873.40%-1169368.85%0.00%
Pretax Profit Margin
-200.78%-474.20%-1848.95%-1036430.46%0.00%
Net Profit Margin
-200.78%-474.21%-1848.97%-1036451.15%0.00%
Continuous Operations Profit Margin
-200.78%-474.21%-1848.97%-1036451.15%0.00%
Net Income Per EBT
100.00%100.00%100.00%100.00%100.00%
EBT Per EBIT
110.21%105.18%98.69%88.63%102.66%
Return on Assets (ROA)
-13.13%-14.57%-47.37%-22.83%-36.47%
Return on Equity (ROE)
-15.68%-17.45%-59.25%-27.17%-39.64%
Return on Capital Employed (ROCE)
-13.72%-16.02%-56.46%-28.89%-37.97%
Return on Invested Capital (ROIC)
-13.71%-16.01%-56.41%-28.77%-37.78%
Return on Tangible Assets
-23.46%-24.33%-96.73%-38.32%-49.90%
Earnings Yield
-5.60%-0.73%-4.43%-2.44%-4.37%
Efficiency Ratios
Receivables Turnover
 2.18 1.06 2.08 0.00 0.00
Payables Turnover
 0.48 0.27 0.43 0.47 0.68
Inventory Turnover
 0.77 0.36 0.74 0.52 0.54
Fixed Asset Turnover
 0.94 0.44 0.18 <0.01 0.00
Asset Turnover
 0.07 0.03 0.03 <0.01 0.00
Working Capital Turnover Ratio
 0.19 0.13 0.10 <0.01 0.00
Cash Conversion Cycle
 -119.85 23.12 -182.65 -77.94 131.94
Days of Sales Outstanding
 167.81 343.27 175.51 0.00 0.00
Days of Inventory Outstanding
 474.19 1.02K 491.14 704.40 671.80
Days of Payables Outstanding
 761.85 1.34K 849.30 782.34 539.87
Operating Cycle
 642.00 1.37K 666.65 704.40 671.80
Cash Flow Ratios
Operating Cash Flow Per Share
 -0.41 -0.43 -0.20 -0.25 -0.87
Free Cash Flow Per Share
 -0.41 -0.43 -0.20 -0.25 -0.97
CapEx Per Share
 <0.01 <0.01 <0.01 <0.01 0.10
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.01 1.01 1.12
Dividend Paid and CapEx Coverage Ratio
 -243.55 -358.18 -190.79 -66.68 -8.64
Capital Expenditure Coverage Ratio
 -243.55 -358.18 -190.79 -66.68 -8.64
Operating Cash Flow Coverage Ratio
 -848.21 -309.41 -66.50 -6.82 -13.69
Operating Cash Flow to Sales Ratio
 -1.83 -3.97 -3.21 -4.00K 0.00
Free Cash Flow Yield
-5.11%-0.61%-0.77%-0.95%-3.68%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -16.99 -138.24 -22.58 -41.02 -22.87
Price-to-Sales (P/S) Ratio
 35.88 650.34 417.49 425.10K 0.00
Price-to-Book (P/B) Ratio
 2.81 23.93 13.38 11.14 9.06
Price-to-Free Cash Flow (P/FCF) Ratio
 -19.56 -163.31 -129.46 -104.75 -27.18
Price-to-Operating Cash Flow Ratio
 -19.64 -163.77 -130.14 -106.32 -30.33
Price-to-Earnings Growth (PEG) Ratio
 -0.14 2.47 -0.28 0.92 0.00
Price-to-Fair Value
 2.81 23.93 13.38 11.14 9.06
Enterprise Value Multiple
 -19.12 -162.10 -23.74 -45.66 -23.77
Enterprise Value
 3.61B 35.75B 13.45B 13.48B 13.40B
EV to EBITDA
 -19.12 -162.10 -23.74 -45.66 -23.77
EV to Sales
 30.86 636.72 412.13 420.78K 0.00
EV to Free Cash Flow
 -16.83 -159.89 -127.80 -103.68 -26.75
EV to Operating Cash Flow
 -16.89 -160.34 -128.47 -105.24 -29.84
Tangible Book Value Per Share
 1.37 1.53 0.71 1.23 2.05
Shareholders’ Equity Per Share
 2.89 2.95 1.97 2.36 2.90
Tax and Other Ratios
Effective Tax Rate
 >-0.01 >-0.01 >-0.01 >-0.01 >-0.01
Revenue Per Share
 0.23 0.11 0.06 <0.01 0.00
Net Income Per Share
 -0.45 -0.51 -1.16 -0.64 -1.15
Tax Burden
 1.00 1.00 1.00 1.00 1.00
Interest Burden
 1.06 1.05 1.00 1.00 1.00
Research & Development to Revenue
 0.65 2.14 5.54 7.45K 0.00
SG&A to Revenue
 1.51 2.61 12.66 0.00 0.00
Stock-Based Compensation to Revenue
 0.00 0.00 0.00 0.00 0.00
Income Quality
 0.91 0.84 0.17 0.39 0.75
Currency in HKD